Oculis (NASDAQ:OCS) Shares Down 9.1% – Should You Sell?

Oculis Holding AG (NASDAQ:OCS) shares were down 9.1% during mid-day trading on Monday . The company traded as low as $14.04 and last traded at $14.09. Approximately 131,275 shares traded hands during trading, an increase of 74% from the average daily volume of 75,395 shares. The stock had previously closed at $15.50.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. HC Wainwright reduced their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Chardan Capital restated a “buy” rating and set a $28.00 target price on shares of Oculis in a research note on Thursday, March 13th. Finally, Robert W. Baird lifted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th.

Oculis Stock Down 7.3 %

The firm has a market cap of $627.42 million, a price-to-earnings ratio of -7.45 and a beta of 0.19. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $20.02 and its 200 day moving average is $17.75.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Analysts forecast that Oculis Holding AG will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Several large investors have recently made changes to their positions in OCS. Geode Capital Management LLC grew its holdings in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares during the last quarter. Bellevue Group AG acquired a new position in shares of Oculis in the 4th quarter valued at $170,000. Bank of America Corp DE increased its stake in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares in the last quarter. XTX Topco Ltd acquired a new stake in Oculis during the 4th quarter worth about $225,000. Finally, Citadel Advisors LLC purchased a new stake in Oculis during the fourth quarter valued at about $389,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.